The group's principal activity is to develop gene therapies for HIV and genetic diseases using its lentiviral vector delivery system. The product of the group include a HIV-based lentiviral vector gene delivery system which is used in administering therapies such as CD4 T cell immunotherapy, hematopoietic stem cell and direct injectable. The group operates from Maryland, United States.
